Debanjana Chatterjee
Stock Analyst at Jones Trading
(4.67)
# 179
Out of 4,981 analysts
11
Total ratings
90%
Success rate
27.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SION Sionna Therapeutics | Initiates: Buy | $46 | $22.81 | +101.67% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $14.29 | +67.95% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $6.76 | +299.41% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $34.01 | +14.67% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $14.01 | +114.13% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $12.36 | +86.16% | 1 | Mar 13, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Hold | n/a | $15.65 | - | 1 | Dec 11, 2024 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $23.38 | +96.75% | 1 | Sep 19, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Buy | $41 | $11.42 | +259.02% | 1 | Sep 17, 2024 |
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $22.81
Upside: +101.67%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $14.29
Upside: +67.95%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $6.76
Upside: +299.41%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $34.01
Upside: +14.67%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $14.01
Upside: +114.13%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $12.36
Upside: +86.16%
Spyre Therapeutics
Dec 11, 2024
Initiates: Hold
Price Target: n/a
Current: $15.65
Upside: -
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $23.38
Upside: +96.75%
Intellia Therapeutics
Sep 17, 2024
Initiates: Buy
Price Target: $41
Current: $11.42
Upside: +259.02%